A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing Cb-839 In Combination With Everolimus (Cbe) Vs. Placebo With Everolimus (Pboe)
Posted Date: May 15, 2019
- Investigator: Muhammad Riaz
- Type of Study: Drug
Calithera CX-839-005
Criteria:
To Be Eligible To Participate In This Study, Patients Must Have A Type Of Advanced Or Metastatic Cle
Keywords:
Cancer, Cx-839-005, Gu, Phase Ii, Renal Cell Carcinoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com